Novadip Biosciences SA

The confluence of data science and molecular biology fuels expectations among biopharma industry leaders for another year of breakthrough innovation in human therapeutics. More than 70 executives and

The first half of 2022 saw the NASDAQ Biotechnology Index lose a quarter of its value. Despite a tentative recovery since then, the IPO window is barely ajar and valuations remain well below the highs

The biotechnology company creator and funder Flagship Pioneering and the Cystic Fibrosis Foundation announced a strategic partnership on 3 November under which the CF Foundation has committed up to

Device Transactions Device financing during 2015's third quarter reached $1.4 billion, a 22% dip from Q2's $1.8 billion total. ( See Exhibit 1. ) Late-stage venture capital rounds represented most of